# V-Wave

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/v-wave

- Industry: Medical Devices & Equipment
- Headquarters: Caesarea, Israel
- Website: www.vwavemedical.com/
- Total disclosed funding: $224M
- Latest round: Series C (Dec 16, 2021)
- Investors on record: 12

## About

Based in Caesarea, Israel, and founded in 2009 by co-founders Ascher Shmulewitz, Ph.D., Gad Keren, MD, and Yaacov Nitzan, V-Wave Ltd. operates as a provider of implantable heart failure treatment solutions to treat heart failure by lowering atrial pressure in patients with left-sided heart conditions. In August 2024, Johnson & Johnson, Inc., agreed to acquire V-Wave Ltd. from Aperture Venture Partners, BioStar Capital, BRM Group, Deerfield Management, Edwards Lifesciences Corporation, Endeavour Vision, Israel Secondary Fund, Johnson & Johnson Innovation, Pontifax Venture Capital, Pura Vida Investments, Quark Venture, and TriVentures for an upfront payment of USD 600 million. As part of the transaction, payment of USD 1.1 billion will be based on additional regulatory and commercial milestones. As of 2024, the company is led by its CEO, Neal Eigler.

The company provides a wide range of cardiovascular medical devices, such as the Ventura Interatrial Shunt System, intended to shunt blood across the interatrial septum to reduce pressure in the heart. The system includes a nitinol hourglass frame and ePTFE encapsulation to prevent tissue growth. Additionally, the firm also provides implantation services using the Ventura Delivery System and clinical research on heart failure.

## Funding rounds

- Series C, Dec 16, 2021, $98M — BRM Group, Aperture Venture Partners, Johnson & Johnson Innovation, Endeavour Vision, Pontifax Venture Capital, Israel Secondary Fund, Deerfield Management, Pura Vida Investments, Triventures, Quark Venture
- Series C, Sep 22, 2020, $28M — BRM Group, Aperture Venture Partners, Johnson & Johnson Innovation, Endeavour Vision, Pontifax Venture Capital, Israel Secondary Fund, Deerfield Management, Pura Vida Investments, Triventures, Quark Venture
- Series C, Apr 26, 2018, $70M — BRM Group, BioStar Capital, Aperture Venture Partners, Johnson & Johnson Innovation, Edwards Lifesciences Corporation, Endeavour Vision, Pontifax Venture Capital, Israel Secondary Fund, Deerfield Management, Pura Vida Investments, Triventures, Quark Venture
- Series B, Jan 11, 2016, $28M — BRM Group, BioStar Capital, Johnson & Johnson Innovation, Edwards Lifesciences Corporation, Pontifax Venture Capital, Pura Vida Investments, Triventures

## Investors

- BRM Group (https://capitalatlas.ai/funds/brm-group) — Series B, Series C
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series B, Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B, Series C
- Edwards Lifesciences Corporation — Series B, Series C
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B, Series C
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series B, Series C
- Triventures (https://capitalatlas.ai/funds/triventures) — Series B, Series C
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C
- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series C
- Israel Secondary Fund (https://capitalatlas.ai/funds/israel-secondary-fund) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series C